Norges Bank Takes Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Norges Bank purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRXFree Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 2,216,612 shares of the biotechnology company’s stock, valued at approximately $13,278,000. Norges Bank owned about 1.08% of BioCryst Pharmaceuticals at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. JGP Global Gestao de Recursos Ltda. bought a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $64,000. MA Private Wealth bought a new stake in BioCryst Pharmaceuticals in the 4th quarter worth approximately $76,000. Pinnacle Wealth Planning Services Inc. bought a new stake in BioCryst Pharmaceuticals in the 4th quarter worth approximately $123,000. Mackenzie Financial Corp lifted its position in BioCryst Pharmaceuticals by 74.7% in the 4th quarter. Mackenzie Financial Corp now owns 23,439 shares of the biotechnology company’s stock worth $140,000 after buying an additional 10,026 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in BioCryst Pharmaceuticals by 387.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 23,692 shares of the biotechnology company’s stock worth $142,000 after buying an additional 18,827 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

Wall Street Analysts Forecast Growth

BCRX has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 7th. Needham & Company LLC restated a “buy” rating and issued a $12.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 7th. Finally, JMP Securities boosted their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “market outperform” rating in a research report on Tuesday, May 7th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

Check Out Our Latest Analysis on BioCryst Pharmaceuticals

Insider Activity

In other BioCryst Pharmaceuticals news, Director Nancy J. Hutson bought 5,000 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, May 20th. The shares were purchased at an average cost of $6.38 per share, with a total value of $31,900.00. Following the completion of the purchase, the director now owns 86,818 shares of the company’s stock, valued at $553,898.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other BioCryst Pharmaceuticals news, Director Alan G. Levin bought 7,861 shares of BioCryst Pharmaceuticals stock in a transaction dated Thursday, May 30th. The shares were purchased at an average cost of $6.36 per share, with a total value of $49,995.96. Following the completion of the purchase, the director now owns 44,951 shares of the company’s stock, valued at $285,888.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Nancy J. Hutson purchased 5,000 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Monday, May 20th. The stock was purchased at an average cost of $6.38 per share, for a total transaction of $31,900.00. Following the completion of the purchase, the director now owns 86,818 shares of the company’s stock, valued at $553,898.84. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 103,601 shares of company stock valued at $596,338. Company insiders own 4.80% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of BioCryst Pharmaceuticals stock opened at $6.74 on Wednesday. The business’s 50 day simple moving average is $5.21 and its two-hundred day simple moving average is $5.54. The stock has a market capitalization of $1.39 billion, a P/E ratio of -6.30 and a beta of 1.87. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $8.96.

BioCryst Pharmaceuticals (NASDAQ:BCRXGet Free Report) last posted its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.06. The business had revenue of $92.80 million for the quarter, compared to analysts’ expectations of $85.62 million. During the same period last year, the firm posted ($0.28) earnings per share. BioCryst Pharmaceuticals’s quarterly revenue was up 34.9% on a year-over-year basis. Sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Profile

(Free Report)

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

See Also

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.